197 related articles for article (PubMed ID: 32497246)
1. Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge.
Riancho J; Delgado-Alvarado M; Andreu MD; Paz-Fajardo L; Arozamena S; Gil-Bea FJ; López de Munaín A
Br J Pharmacol; 2021 Mar; 178(6):1269-1278. PubMed ID: 32497246
[TBL] [Abstract][Full Text] [Related]
2. Clinical and preclinical evidence of somatosensory involvement in amyotrophic lateral sclerosis.
Riancho J; Paz-Fajardo L; López de Munaín A
Br J Pharmacol; 2021 Mar; 178(6):1257-1268. PubMed ID: 32673410
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy.
Palomo V; Nozal V; Rojas-Prats E; Gil C; Martinez A
Br J Pharmacol; 2021 Mar; 178(6):1316-1335. PubMed ID: 32737989
[TBL] [Abstract][Full Text] [Related]
4. Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis.
Klingl YE; Pakravan D; Van Den Bosch L
Br J Pharmacol; 2021 Mar; 178(6):1353-1372. PubMed ID: 32726472
[TBL] [Abstract][Full Text] [Related]
5. What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for therapy.
Manzano R; Toivonen JM; Moreno-Martínez L; de la Torre M; Moreno-García L; López-Royo T; Molina N; Zaragoza P; Calvo AC; Osta R
Br J Pharmacol; 2021 Mar; 178(6):1279-1297. PubMed ID: 32986860
[TBL] [Abstract][Full Text] [Related]
6. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis.
Herrando-Grabulosa M; Gaja-Capdevila N; Vela JM; Navarro X
Br J Pharmacol; 2021 Mar; 178(6):1336-1352. PubMed ID: 32761823
[TBL] [Abstract][Full Text] [Related]
7. Targeting the CB
Rodríguez-Cueto C; García-Toscano L; Santos-García I; Gómez-Almería M; Gonzalo-Consuegra C; Espejo-Porras F; Fernández-Ruiz J; de Lago E
Br J Pharmacol; 2021 Mar; 178(6):1373-1387. PubMed ID: 33486755
[TBL] [Abstract][Full Text] [Related]
8. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules.
Buratti E
Br J Pharmacol; 2021 Mar; 178(6):1298-1315. PubMed ID: 32469420
[TBL] [Abstract][Full Text] [Related]
9. Redox-based therapeutics in neurodegenerative disease.
McBean GJ; López MG; Wallner FK
Br J Pharmacol; 2017 Jun; 174(12):1750-1770. PubMed ID: 27477685
[TBL] [Abstract][Full Text] [Related]
10. The increasing importance of environmental conditions in amyotrophic lateral sclerosis.
Riancho J; Bosque-Varela P; Perez-Pereda S; Povedano M; de Munaín AL; Santurtun A
Int J Biometeorol; 2018 Aug; 62(8):1361-1374. PubMed ID: 29713861
[TBL] [Abstract][Full Text] [Related]
11. Reviewing the evidence for viruses as environmental risk factors for ALS: A new perspective.
Celeste DB; Miller MS
Cytokine; 2018 Aug; 108():173-178. PubMed ID: 29684753
[TBL] [Abstract][Full Text] [Related]
12. Multi-angle development of therapeutic methods for Alzheimer's disease.
Hoshi M
Br J Pharmacol; 2021 Feb; 178(4):770-783. PubMed ID: 32592177
[TBL] [Abstract][Full Text] [Related]
13. Cellular metabolism and diseases.
Maiuri MC; Maffia P
Br J Pharmacol; 2021 May; 178(10):2031-2033. PubMed ID: 33932230
[TBL] [Abstract][Full Text] [Related]
14. Shedding light on the roles of liver X receptors in cancer by using chemical probes.
Pontini L; Marinozzi M
Br J Pharmacol; 2021 Aug; 178(16):3261-3276. PubMed ID: 32673401
[TBL] [Abstract][Full Text] [Related]
15. Targeting glial cannabinoid CB
Espejo-Porras F; García-Toscano L; Rodríguez-Cueto C; Santos-García I; de Lago E; Fernandez-Ruiz J
Br J Pharmacol; 2019 May; 176(10):1585-1600. PubMed ID: 29574689
[TBL] [Abstract][Full Text] [Related]
16. Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives.
Ralli M; Lambiase A; Artico M; de Vincentiis M; Greco A
Isr Med Assoc J; 2019 Jul; 21(7):438-443. PubMed ID: 31507117
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of bisphosphonates in pain.
Tzschentke TM
Br J Pharmacol; 2021 May; 178(9):1973-1994. PubMed ID: 31347149
[TBL] [Abstract][Full Text] [Related]
18. Possible mechanisms of cancer prevention by nicotinamide.
Buqué A; Bloy N; Kroemer G; Galluzzi L
Br J Pharmacol; 2021 May; 178(10):2034-2040. PubMed ID: 32383227
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (Review).
Martin LJ; Price AC; Kaiser A; Shaikh AY; Liu Z
Int J Mol Med; 2000 Jan; 5(1):3-13. PubMed ID: 10601567
[TBL] [Abstract][Full Text] [Related]
20. Risk of amyotrophic lateral sclerosis and other motor neuron disease among men with benign prostatic hyperplasia: a population-based cohort study.
Sørensen TT; Horváth-Puhó E; Nørgaard M; Ehrenstein V; Henderson VW
BMJ Open; 2019 Jul; 9(7):e030015. PubMed ID: 31278107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
